PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Shows the trajectory of a company's cash-generation capacity. Consistent growth in operating and free cash flow suggests a robust, self-funding business model—crucial for value investors seeking undervalued, cash-rich opportunities.
16.61%
Net income growth at 50-75% of TRAW's 26.66%. Martin Whitman would worry about lagging competitiveness unless expansions are planned.
4.17%
Some D&A expansion while TRAW is negative at -25.00%. John Neff would see competitor’s short-term profit advantage unless expansions here deliver big returns.
-100.00%
Negative yoy deferred tax while TRAW stands at 0.00%. Joel Greenblatt would consider near-term tax obligations but a possible advantage if competitor's deferrals become a burden later.
-2.08%
Both cut yoy SBC, with TRAW at -30.85%. Martin Whitman would view it as an industry shift to reduce stock-based pay or a sign of reduced expansions.
-115.45%
Both reduce yoy usage, with TRAW at -467.27%. Martin Whitman would find an industry or cyclical factor prompting leaner operational approaches.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-138.13%
Negative yoy AP while TRAW is 5.27%. Joel Greenblatt would see quicker payments or less reliance on trade credit than competitor, unless expansions are hindered.
-68.80%
Both reduce yoy usage, with TRAW at -211.87%. Martin Whitman would suspect an industry or cyclical factor pulling back on these items.
119.47%
Lower 'other non-cash' growth vs. TRAW's 338.62%, indicating steadier reported figures. David Dodd would confirm no missed necessary write-downs or gains.
9.84%
Some CFO growth while TRAW is negative at -21.58%. John Neff would note a short-term liquidity lead over the competitor.
98.37%
CapEx growth of 98.37% while TRAW is zero at 0.00%. Bruce Berkowitz would see a mild cost burden that must yield returns in future revenue or margins.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
98.37%
We expand invests by 98.37% while TRAW is zero at 0.00%. Bruce Berkowitz sees a moderate outflow that must be justified by returns vs. competitor’s stable approach.
64.41%
Debt repayment growth of 64.41% while TRAW is zero at 0.00%. Bruce Berkowitz sees a mild advantage that can reduce interest costs unless expansions demand capital here.
-34.38%
Negative yoy issuance while TRAW is 0.00%. Joel Greenblatt sees a near-term advantage in avoiding dilution unless competitor invests more effectively with the new shares.
No Data
No Data available this quarter, please select a different quarter.